Endourology Wednesday June 23 2021

摘要

Long-term medical management of benign prostatic hyperplasia (BPH) includes use of 5-alpha reductase inhibitors (5ARI) and alphablockers (AB). Studies have demonstrated an increased risk of comorbidities, including cardiac failure and diabetes mellitus, with use of these medications, raising safety concerns. This study aims to determine the risk of developing diabetes with the use of AB and 5ARI in combination, as well as monotherapy.